Compare TRMK & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRMK | ADPT |
|---|---|---|
| Founded | 1889 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 1987 | 2019 |
| Metric | TRMK | ADPT |
|---|---|---|
| Price | $40.63 | $15.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $42.67 | $16.60 |
| AVG Volume (30 Days) | 276.0K | ★ 3.0M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 10.82 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $773,338,000.00 | $252,754,000.00 |
| Revenue This Year | $58.57 | $50.81 |
| Revenue Next Year | $4.65 | $1.17 |
| P/E Ratio | $11.10 | ★ N/A |
| Revenue Growth | ★ 55.58 | 42.57 |
| 52 Week Low | $29.77 | $5.81 |
| 52 Week High | $41.34 | $20.76 |
| Indicator | TRMK | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 44.33 |
| Support Level | $37.37 | $14.58 |
| Resistance Level | $41.22 | $16.26 |
| Average True Range (ATR) | 1.13 | 1.13 |
| MACD | 0.22 | -0.36 |
| Stochastic Oscillator | 85.65 | 13.75 |
Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).